Novartis DRB436 TMT212: Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory High Grade

  • Goldman, Stewart (PD/PI)

Project: Research project

Project Details

StatusActive
Effective start/end date1/1/1812/31/22

Funding

  • Novartis Pharmaceuticals Corporation
  • Novartis Pharmaceuticals Corporation